DoubleLine Foresees Further Treasury Yield Curve Steepening, Risk of Elevated Term Premium
TAMPA, Fla., Oct. 3, 2025 /PRNewswire/ -- The U.S. Treasury yield curve, DoubleLine Global…
HKUST Scientists Reveal Critical Impacts of a Chinese Genetic Risk Factor in Alzheimer’s Disease
HONG KONG, Oct. 2, 2025 /PRNewswire/ -- A landmark study conducted by…
Envalior at K 2025 with material solutions to help customers reduce Time, Risk, Costs, and CO
At K 2025, Envalior will present its latest innovations in Sustainable &…
The Hidden Genetic Threat Putting 1 in 5 at Cardiovascular Disease Risk: Global Experts Call for Action on Elevated Lipoprotein(a)
Cardiovascular disease (CVD) kills nearly 18 million people each year, more than…
KuCoin Futures Implements Trading Upgrade for Improved Execution and Risk Management
PROVIDENCIALES, Turks and Caicos Islands, Sept. 19, 2025 /PRNewswire/ -- KuCoin, a leading…
Bigg Boss 19: Nominations Drama Unfolds – Who’s Safe and Who’s at Risk?
Hello, friends! Welcome to another exciting update from Bigg Boss 19, brought…
EADV Congress 2025: Atopic eczema linked to significantly higher risk of suicidal thoughts
PARIS, Sept. 17, 2025 /PRNewswire/ -- A new international study presented today…
Phemex Launches Multi-Assets Mode to Enhance Trading Efficiency and Risk Management
APIA, Samoa, Sept. 12, 2025 /PRNewswire/ -- Phemex, the most efficient crypto…
Novo Nordisks Wegovy cuts risk of heart attack, stroke or death by 57% compared to tirzepatide in real-world study of people with obesity and cardiovascular disease
Compared with tirzepatide, Wegovy® (semaglutide 2.4 mg) showed a significant 57% greater…
New REDUCE-IT Analyses Presented at ESC 2025 Include Data Showing VASCEPA/VAZKEPA (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
-- 2025 ESC/EAS Dyslipidemia Guideline Focused Update Reaffirms High Dose Icosapent Ethyl…
